Harmony's revenue grew from $184.7M in 2025Q1 to $268.9M in 2026Q3, but year-over-year growth decelerated to 12.3% in the latest quarter from 30.3% in 2026Q2, suggesting WAKIX demand is maturing.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.81-25.7% vs $1.09 | $269M-1.2% vs $272M |
Q3 2026 Aug 4, 2026 | $1.28+33.9% vs $0.96 | $261M+4.2% vs $251M |
Q2 2026 May 7, 2026 | $0.55-27.6% vs $0.76 | $215M-2.5% vs $221M |
Q1 2026 Feb 24, 2026 | $0.38-54.8% vs $0.84 | $244M+1.4% vs $240M |
Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
Harmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-year WAKIX net revenue guidance of $1 billion to $1.04 billion and said it expects to exceed $1 billion in annual WAKIX revenue for the first time.
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.
Benchmark HRMY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Harmony Biosciences Holdings, Inc. (HRMY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $33.11 | $1.92B | 11.06 | 21.51% | 18.05% | 18.55% | — | |
| $234.76 | $14.75B | 73.75 | 4.88% | 4.37% | 4.62% | — | |
| $16.55 | $3.51B | 48.08 | 26.93% | 15.67% | 17.07% | — | |
| $132.37 | $6.81B | -44.14 | 65.55% | -18.18% | -189.73% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — |
Harmony Biosciences Holdings, Inc. (HRMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Harmony Biosciences Holdings, Inc. (HRMY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Oct 13, 2026·SEC
Aug 4, 2026·SEC
Get notified when HRMY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Harmony Biosciences Holdings, Inc. (HRMY) stock FAQ — growth, dividends, profitability & financials explained
Harmony Biosciences Holdings, Inc. (HRMY) reported $989.4M in revenue over the trailing twelve months. Revenue was $868.5M in fiscal year 2025.
Harmony Biosciences Holdings, Inc. (HRMY) grew revenue by 19.8% over the trailing twelve months, compared with the twelve months before.
Yes. Harmony Biosciences Holdings, Inc. (HRMY) earned $178.6M in net income over the trailing twelve months (a 18.1% net margin).
Harmony Biosciences Holdings, Inc. (HRMY) had a return on equity (ROE) of 18.5% over the trailing twelve months. That is above the market's typical 10-15%.
Harmony Biosciences Holdings, Inc. (HRMY) generated $322.9M in free cash flow over the trailing twelve months.
